Clinical Trial: Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

This study is currently recruiting patients.
Verified by Pfizer September 2005

Sponsored by: Pfizer
Information provided by: Pfizer Identifier: NCT00150332


Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
Condition Intervention Phase
Staphylococcus aureus
Methicillin resistance
 Drug: linezolid
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title: Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-Label, Multi-Center Trial

Further Study Details: 
Primary Outcomes: Resolution of infection at the time of completion of therapy
Secondary Outcomes: Adverse events
Expected Total Enrollment:  20

Study start: January 2003


Ages Eligible for Study:  16 Years and above,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • infection due to methicillin-resistant Staphylococcus aureus

Exclusion Criteria:

  • hypersensitivity to linezolid

Location and Contact Information

Please refer to this study by identifier  NCT00150332

Toshide Ito      81-3-5039-7449

      Pfizer Investigational Site, Fukuoka,  813-0025,  Japan; Recruiting

      Pfizer Investigational Site, Fukuoka,  811-0213,  Japan; Recruiting

      Pfizer Investigational Site, Nagasaki,  852-8501,  Japan; Recruiting

      Pfizer Investigational Site, Okayama,  700-8505,  Japan; Completed

      Pfizer Investigational Site, Okayama,  703-8275,  Japan; Recruiting

Japan, Chiba
      Pfizer Investigational Site, Kamogawa,  Chiba,  296-0041,  Japan; Recruiting

Japan, Fukuoka
      Pfizer Investigational Site, Onga-gun,  Fukuoka,  807-0051,  Japan; Recruiting

Japan, Hokkaido
      Pfizer Investigational Site, Sapporo,  Hokkaido,  006-8555,  Japan; Completed

      Pfizer Investigational Site, Sappopro,  Hokkaido,  060-8648,  Japan; Completed

Japan, Ibaraki
      Pfizer Investigational Site, Moriya,  Ibaraki,  302-0118,  Japan; Recruiting

Japan, Nagasaki
      Pfizer Investigational Site, Isahaya,  Nagasaki,  854-8501,  Japan; Recruiting

Japan, Okayama
      Pfizer Investigational Site, Kurashiki,  Okayama,  701-0912,  Japan; Recruiting

Japan, Osaka
      Pfizer Investigational Site, Suita,  Osaka,  565-8565,  Japan; Recruiting

Japan, Saitama
      Pfizer Investigational Site, Iruma-gun,  Saitama,  350-0495,  Japan; Recruiting

Japan, TOKYO
      Pfizer Investigational Site, Kodaira-shi,  TOKYO,  187-0004,  Japan; Recruiting

Study chairs or principal investigators

Pfizer Call Center,  Study Director,  Pfizer   

More Information

Study ID Numbers:  M12600067
Last Updated:  September 7, 2005
Record first received:  September 6, 2005 Identifier:  NCT00150332
Health Authority: Japan: Ministry of Health, Labor and Welfare processed this record on 2005-09-13


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us